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Abstract
Background: The Caribbean vervet monkey (Chlorocebus aethiops sabaeus) is a potentially valuable animal model of neurodegenerative disease. However, the trajectory of
aging in vervets and its relationship to human disease is incompletely understood.
Methods: To characterize biomarkers associated with neurodegeneration, we measured cerebrospinal fluid (CSF) concentrations of Aβ1–40, Aβ1–42, total tau, and p-tau181
in 329 members of a multigenerational pedigree. Linkage and genome-wide association were used to elucidate a genetic contribution to these traits.
Results: Aβ1–40 concentrations were significantly correlated with age, brain total surface area, and gray matter thickness. Levels of p-tau181 were associated with cerebral
volume and brain total surface area. Among the measured analytes, only CSF Aβ1–40
was heritable. No significant linkage (LOD > 3.3) was found, though suggestive linkage
was highlighted on chromosomes 4 and 12. Genome-wide association identified a
suggestive locus near the chromosome 4 linkage peak.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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Conclusions: Overall, these results support the vervet as a non-human primate model
of amyloid-related neurodegeneration, such as Alzheimer’s disease and cerebral amyloid angiopathy, and highlight Aβ1–40 and p-tau181 as potentially valuable biomarkers of
these processes.
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1 | INTRODUCTION

Fagan et al., 2014; Motter et al., 1995; Sunderland et al., 2003; Tapiola

Nonhuman primates, unlike most other model organisms (e.g. mice

is a more accurate biomarker of AD than Aβ1–42 alone (Dumurgier

and rats), are known to develop age-related amyloid pathology

et al., 2015; Hansson et al., 2007; Lewczuk, Lelental, Spitzer, Maler,

et al., 2009). Some authors have reported that the Aβ1–42/Aβ1–40 ratio

similar to that of Alzheimer’s disease (AD) in humans (Kalinin et al.,

& Kornhuber, 2015; Wiltfang et al., 2007). CSF tau and phosphory-

2013; Ndung’u et al., 2012; Podlisny, Tolan, & Selkoe, 1991; Rosen

lated tau, particularly at Threonine 181, are increased in AD patients

et al., 2008; Toledano, Álvarez, López-Rodríguez, Toledano-Díaz, &

(Andreasen et al., 1999; Fagan et al., 2014; Sunderland et al., 2003;

Fernández-Verdecia, 2014), and have complex behavioral phenotypes

Tapiola et al., 2009; Vandermeeren et al., 1993), however the mech-

closer to that in humans than other species could achieve. AD-related

anism of tau egress into the CSF and the relation to tau pathology

genes, such as those encoding β-amyloid (Aβ, APP) and tau (MAPT),

is unclear. These CSF biomarkers have also been shown to change

are also highly similar (Holzer, Craxton, Jakes, Arendt, & Goedert,

longitudinally in patients with familial forms of AD and predict clinical

2004; Podlisny et al., 1991). Tau pathology, though reported in great

disease progression (Bateman et al., 2012; Fagan et al., 2007; Hansson

apes, baboons, and lesser primates, appears far less abundant than

et al., 2006). Collection of CSF enables the study of amyloid pathology

in human disease, and distribution of amyloid pathology differs from

across a large sample of vervets and is a first step toward understand-

that in human AD (Heuer, Rosen, Cintron, & Walker, 2012; Toledano

ing the translatability of CSF biomarkers between human and vervet.

et al., 2014). Correlation of amyloid pathology with cognition and atro-

The Vervet Research Colony (VRC) was established from vervets

phy has been observed, but to a lesser degree compared with humans

captured in St. Kitts and Nevis, and maintained as a single extended

(Heuer et al., 2012; Toledano et al., 2014).

pedigree (Jasinska et al., 2012), thereby providing a large sample ideal

The Caribbean vervet monkey (Chlorocebus aethiops sabaeus,

for mapping quantitative traits and study of complex neurobiologic

also known as the African green monkey), an Old World monkey, is

traits. Additionally, the wide distribution of subjects with ages across

well-suited as a model of aging and neurodegenerative disease; com-

the normal vervet lifespan enables the study of age-related disease;

pared to rhesus macaques, vervets are more available and carry fewer

vervets typically live to 11–13 years in the wild, but up to 25 years

pathogens. Vervets display AD-like pathology, including accumulation

in captivity (Magden, Mansfield, Simmons, & Abee, 2015); the oldest

of Aβ-containing cerebral plaques associated with reactive astrocyto-

animal in the VRC was a female that recently died at 29.1 years of age.

sis, dystrophic neurites, and vascular Aβ immunoreactivity resembling

Previous work in the VRC reported on the acquisition and analysis of

cerebral amyloid angiopathy (CAA), but unlike humans have relatively

neuroanatomic phenotypes using high-resolution structural MRI in a

preserved cognition that does not appear correlated with plaque bur-

large number of colony members (Fears et al., 2009, 2011). In the cur-

den and demonstrate scant phosphorylated tau aggregates (Heuer

rent study, we extend the neurobiologic characterization of the VRC

et al., 2012; Kalinin et al., 2013; Lemere et al., 2004; Toledano et al.,

through the acquisition and analysis of CSF biomarkers in the context

2014). The high incidence of Aβ immunoreactive plaques in vervets

of the rich genetic and phenotypic information available through the

older than 20 years of age (Kalinin et al., 2013) suggests that they

VRC.

occur as part of the normal aging of the vervet.
In humans, cerebrospinal fluid (CSF) harbors useful biomarkers of
neurodegenerative disease. CSF levels of Aβ and tau change with AD.
Aβ exists in several isoforms, predominantly composed of residues
1–40 (Aβ1–40) and residues 1–42 (Aβ1–42). Aβ1–40 is the most abundant isoform, but CSF concentration differences of Aβ1–40 are gener-

2 | METHODS AND MATERIALS
2.1 | Vervet pedigree
This investigation was conducted as approved by the Animal Research

ally subtle in AD (Fagan et al., 2007, 2014). Indeed, the shorter Aβ1–40

Committee in the Office for Protection of Research Subjects at

isoform is more predominant in CAA, and a decrease in CSF Aβ1–40 is

UCLA and the Institutional Animal Care and Use Committees at the

associated with CAA (Verbeek et al., 2009). Aβ1–42 is less abundant,

Sepulveda Veterans Administration Medical Center and the Wake

but constitutes the major isoform present in neuritic plaques in hu-

Forest School of Medicine. The vervet subjects analyzed in this study

mans and in vervets and is more fibrillogenic. CSF Aβ1–42 has been

are part of a pedigree that has included more than 1,000 animals since

consistently shown to be decreased in AD (Andreasen et al., 1999;

its founding. The VRC was established during the 1970s and 1980s

|
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from 58 founder animals that were captured from a wild population

directions using six accompanying standards provided in the kit. All

in the islands of St. Kitts and Nevis. Vervet monkeys originally arrived

assays were run in duplicate. Measurements with coefficient of vari-

in the Caribbean Islands in the 1600s on trading ships from Africa

ation (CV) >25% or bead count <30 were excluded in quality control.

(McGuire, 1974). Since the founding of the colony, breeding has been
managed to provide a species-typical social environment for developing offspring and to promote genetic diversity, while preserving each

2.3 | Neuroimaging analysis

of the original matrilines to simulate the social structure of wild-living

Neuroimaging data were acquired in 2007; details of the image ac-

troops. Female offspring remain in the breeding groups, and males are

quisition and pre-processing protocol have been described previously

removed to separate housing at 4 years of age as previously described

(Fears et al., 2009). To generate high signal-to-noise images, nine

(Fairbanks et al., 2004). Adult males born in different social groups are

separate structural scans were acquired from 357 animals (256 fe-

introduced into the breeding groups at 3–4 year intervals; because

males and 101 males) using an 8-channel high-resolution knee array

no new animals have been imported for several decades, extensive

coil as a receiver in a 1.5 Tesla Siemens (Erlanger) Symphony unit.

inbreeding occurs. The average inbreeding coefficient (probability

The images were acquired as axial T1-weighted volumes with a 3D

that a subject receives two alleles identical-by-descent) in the colony

magnetization prepared rapid acquisition gradient echo (MPRAGE);

was recently characterized at 0.006, with animals with non-zero in-

TR = 1,900 msec, TE = 4.38 msec, TI = 1,100 msec, flip angle = 15

breeding coefficient ranging from 0.004 to 0.25 (mean 0.05; Freimer

degrees, and voxel resolution = 0.5 mm in all three planes. The nine

et al., 2007). The high level of inbreeding facilitates genetic mapping

separate images were aligned to each other in pair-wise rigid body

in our study population, improving the effective sample size for as-

registrations and averaged together prior to segmentation. The age at

sociation and providing a high informative pedigree for linkage. The

CSF biomarker collection and measurement (performed in 2012) was

genetic architecture and genetic control of traits may not reflect out-

approximately 5 years following the age at MRI measurement (per-

bred populations.

formed in 2007); analyses were performed with each animal from the

Vervets were fed commercial laboratory chow ad lib, supple-

CSF analysis paired with their own earlier scan data.

mented by fresh fruits and produce. Specifically, the vervet chow has

Details of the six brain phenotypes investigated in the initial as-

primarily been LabDiet 5038 (“Monkey Diet”), with several exceptions.

sociation analysis have been described previously (Fears et al., 2009).

During 2004 to 2008, animals were fed LabDiet 5052 (“Fiber-Balanced

For the secondary analysis of regional cortical phenotypes, the images

Monkey Diet”) as previously described (Fairbanks, Blau, & Jorgensen,

were segmented to generate cortical thickness and surface area mea-

2010). For 6 months in mid 2009, animals were fed LabDiet 5L0P

sures using a combination of manual and automated methods. Thirty

(“Typical American Primate Diet”) as previously described (Voruganti

images were manually segmented into 29 regions based on each sub-

et al., 2013).

ject’s anatomical details. The 30 manually segmented images were
used as input for the Freesurfer (RRID:SCR_001847) program ‘mri_ca_

2.2 | CSF biomarker measurements

train’ to generate a probabilistic anatomical map (https://surfer.nmr.
mgh.harvard.edu/fswiki/mri_ca_train) that was then used to segment

CSF was collected from the cisterna magna of each animal under

the entire dataset. The Freesurfer segmented images were then in-

a protocol approved by the Animal Research Committee at the

spected and manually adjusted to correct gross segmentation errors.

University of California, Los Angeles, as previously described (Freimer
et al., 2007). CSF protein concentrations were measured at the Knight
Alzheimer’s Disease Research Center (ADRC) Biomarker Core Lab

2.4 | Statistical analysis

at Washington University in St. Louis as previously described (Shaw

Brain-CSF associations were tested using linear regression as

et al., 2011). Concentrations of CSF Aβ1–40 were measured with

implemented with the Sequential Oligogenic Linkage Analysis

the INNOTEST β-AMYLOID(1–40) solid-phase enzyme immunoassay

Routines (SOLAR) software package (Almasy & Blangero, 1998;

(Innogenetics N.V., Ghent, Belgium). Briefly, the amyloid peptides are

RRID:SCR_000850). SOLAR uses the pedigree structure to adjust for

first captured by the 2G3 monoclonal antibody, and quantified with a

the dependency structure among the subjects that would otherwise

biotinylated monoclonal antibody, 3D6. The protein is then detected

violate assumptions for standard linear regression methods. For the

using a peroxidase-labeled streptavidin readout. Concentrations of

neuroimaging measures, age and sex were controlled as covariates in

CSF Aβ1–42, tau, and phosphorylated tau (p-tau181) were measured

a linear regression model; the residuals were then associated with CSF

simultaneously with the INNO-BIA AlzBio3 fluorimetric immuno-

traits. The procedure of Benjamini and Hochberg was used to correct

assay (Innogenetics N.V., Gent, Belgium). Briefly, the proteins are

for multiple testing to identify significant associations in the initial set

first captured on beads by specific monoclonal antibodies – 4D7A3

of six neuroimaging traits with the four CSF traits (24 tests), using a

for Aβ1–42, AT120 for tau, and AT270 for p-tau181. Additional bioti-

false discovery rate (FDR) threshold of 0.05. In the secondary analy-

nylated antibodies are then used to quantify the proteins – 3D6 for

sis of regional cortical measures of thickness and surface area with

Aβ1–42, and HT7 for tau and p-tau181. The proteins are then detected

Aβ1–40 and p-tau181 traits, the procedure of Benjamini and Hochberg

using a phycoerythrin-labeled streptavidin readout. Calibration of the

was similarly used, applied to each of the two sets of association tests

standard curve was performed as described in the manufacturer’s

independently (29 tests per set).

4 of 10

|

CHEN et al.

World Monkeys (approximately 25 million years), and the similarity

2.5 | Heritability calculations and linkage analysis

in genome size between human and vervet (Warren et al., 2015).

A whole-genome sequencing strategy was used to identify and type
vervet polymorphisms, as previously described (Huang et al., 2015).
The vervet pedigree was visualized using the “kinship2” package.
Heritability analysis was performed using SOLAR. The variance component models of SOLAR assume normality in the trait distributions;

3 | RESULTS
3.1 | Vervet subject characteristics

therefore, in order to force the distribution of CSF biomarker phe-

Animals were selected from a complex, nine-generation-deep vervet

notypes to approximately normal and correct for skew and kurtosis,

pedigree with a high degree of consanguineous mating. Following

the inverse normal transformation was used. For each phenotype,

quality control procedures (see Methods), CSF concentrations of

the correlation to age and sex covariates was evaluated. Residuals

Aβ1–40, Aβ1–42, tau, and p-tau181 (tau phosphorylated at Thr181) were

after regression for significant covariates were used in downstream

obtained in a total of 329 animals (Table 1). Unexpectedly, for each

analyses. Quantitative polygenic screening was performed as previ-

demographic category, mean total tau concentrations were lower than

ously described using the “polygenic” function of SOLAR, yielding an

those of p-tau181. The distributions of CSF concentrations of Aβ1–40,

estimate of the narrow-sense polygenic heritability (h2, a measure of

Aβ1–42, tau, and p-tau181 were skewed (Table 1, Figure S1). Levels of

the fraction of phenotypic variance due to additive genetic factors); a

Aβ1–40 were inversely correlated with age (r = −.17, p = .00094), while

p-value for this estimate; and the proportion of variance attributable

levels of Aβ1–42, tau, and p-tau181 were not (r = −.039, .0086, .07, and

to covariates. Genetic mapping was performed using multipoint link-

p = .47, .87, and .19, respectively; Figure S2). The correlation between

age analysis implemented in SOLAR. First, the multipoint identity-by-

age and CSF Aβ1–40 was consistent when excluding animals >10 years

descent (IBD) relationships were computed for the vervet pedigree as

of age (r = −.13, p = .093).

previously described (Huang et al., 2015). A multipoint linkage scan
was then run with an interval of 5 centimorgans. LOD scores were
old of 3.3 as previously proposed (Lander & Kruglyak, 1995). Zero-in

3.2 | Species differences and polymorphisms in the
vervet β-amyloid and tau proteins

scans at finer scales were performed at peaks with LOD scores >2. The

The antibody-based CSF assays were designed and validated for hu-

confidence region around a peak was defined as the region spanned

mans; therefore, we evaluated whether species-specific differences

by 1 LOD intervals to either side of the peak.

or polymorphisms in the vervet orthologs of APP (encoding the amy-

considered suggestive at a threshold of 1.9, and significant at a thresh-

loid precursor protein) and MAPT (encoding tau) could affect the performance of the antibodies.

2.6 | Association testing

Species-specific differences between vervet and human in the an-

The EMMAX software was used to map genetic associations

tibody epitope regions were first identified. Across the Aβ peptide the

with CSF biomarker phenotypes in the vervet (Kang et al., 2010;

human and vervet proteins were identical, including the 2G3, 4D7A3,

RRID:SCR_008217). EMMAX uses a variance component model to

and 3D6 epitope regions (Figure S3). Differences were found between

account for high relatedness among the vervet subjects (estimated

the human tau protein and the vervet ortholog, including a single

from pairwise kinship calculated by identity-by-state). A linear mixed

amino acid substitution (threonine to alanine) in the AT120 epitope

model was then fit to the data and used to calculate the association.

region, which could affect the results for total tau concentration.

We used standard genome-wide significant thresholds from hu−8

−6

mans (significant at p < 5 × 10 , suggestive at p < 5 × 10 ; Risch &

Coding polymorphisms across vervet subjects were then identified
to determine whether inter-individual differences in the polypeptide

Merikangas, 1996), which should approximate appropriate values in

sequence of Aβ or tau could confound their quantification. In our

vervet given the relatively recent divergence between apes and Old

cohort, polymorphisms were identified in APP (Ala15Ser) and MAPT

N (%)
All
0–5 years old

Ab40 mean
(SD), pg/ml

Ab42 mean
(SD), pg/ml

Tau mean
(SD), pg/ml

pTau mean
(SD), pg/ml

329 (100)

10267 (4250)

506 (166)

23 (6)

30 (11)

87 (26)

11047 (3880)

505 (181)

23 (5)

30 (10)

5–10 years old

99 (30)

10282 (3819)

503 (169)

22 (6)

29 (12)

10–15 years old

78 (24)

10094 (4509)

499 (162)

23 (8)

28 (11)

15–20 years old

45 (14)

10289 (5332)

499 (168)

23 (8)

33 (11)

20+ years old

20 (6)

7416 (2939)

556 (92)

22 (4)

36 (14)

Male
Female

55 (17)

11151 (4371)

529 (154)

21 (2)

33 (11)

274 (83)

10088 (4211)

501 (168)

23 (7)

29 (11)

T A B L E 1 Characteristics of vervet
subjects used in the analysis, at the time of
CSF collection

|

CHEN et al.

TABLE 2

5 of 10

Associations of global measures of brain size with CSF biomarkers
Ab40

Ab42

tau

N

β

p

N

β

p

N

Cerebral volume

209

0.09

.09

200

Cerebellar volume

209

0.03

.58

200

−.007

.90

207

.002

.98

207

Corpus callossum cross
sectional area

209

0.12

.024

200

−.07

.22

207

Hippocampal volume

209

0.14

.013

Total gray matter
thickness

206

0.17

.007

200

−.03

.58

207

197

.05

.50

204

Total surface area

206

0.14

.006

197

−.005

.93

204

p-tau
p

N

β

p

.94

204

−.17

.001

.53

204

−.11

.039

.91

204

−.12

.018

−.03

.58

204

−.12

.039

−.07

.26

201

−.13

.05

.93

201

−.14

.008

β
.004
−.03
.006

.005

(Gly148Arg and Leu213Pro). None overlapped with the antibody epi-

Hypothesis tests for each association were corrected for multiple

tope regions; furthermore, no associations between these polymor-

comparisons using the method of Benjamini and Hochberg, yield-

phisms and quantified CSF concentrations were observed (Figure S4).

ing adjusted p-values (pBH) that control for the false discovery
rate. Concentrations of Aβ1–40 were correlated with increased gray

3.3 | Relation between CSF biomarker level and
brain structure

matter thickness across many brain regions, including the orbital
frontal gyri (linear regression coefficient β = 0.26, pBH = 0.002), lingual gyrus (β = 0.19, pBH = 0.040), inferior frontal gyrus (β = 0.17,

Brain imaging phenotypes and genetic data had been collected as part

pBH = 0.040), precuneus (β = 0.18, pBH = 0.040), angular gyrus

of a previous study (Fears et al., 2009). In total, both CSF biomarker

(β = 0.17, pBH = 0.040), middle frontal gyrus (β = 0.17, pBH = 0.040),

measurements and neuroimaging data were measured in 209 animals. In

inferior precentral gyrus (β = 0.17, pBH = 0.040), superior precen-

general, this subgroup had fewer animals of very young age, due to the

tral gyrus (β = 0.16, pBH = 0.044), superior frontal gyrus (β = 0.16,

time interval between studies (Figure S5). To determine the relationship

pBH = 0.044), postcentral gyrus (β = 0.16, pBH = 0.044), and lateral

between the CSF concentrations of Aβ1–40, Aβ1–42, tau, and p-tau181

occipital gyri (β = 0.16, pBH = 0.047; Table S1, Figure 2). Significant

with neuroimaging phenotypes, we initially calculated the correlations

correlations with surface area were limited to the lateral occipi-

of CSF biomarker concentrations with six global measures (cerebral

tal gyrus (β = 0.20, PBH = 0.027). Concentrations of p-tau181 were

volume, cerebellar volume, hippocampal volume, cross-sectional area

correlated with decreased gray matter thickness in the fusiform

of the corpus callosum, total gray matter thickness, and total surface

gyrus (β = −0.20, pBH = 0.022), and surface area of the corpus cal-

area; see Table 2 and Figure 1), after correction for age and sex. At a

losum (β = −0.22, pBH = 0.009) and inferior occipital gyri (β = −0.17,

nominal significance threshold (p = .05), Aβ1–40 was correlated with

pBH = 0.049). The direction of relationship was largely consistent

corpus callosum cross-sectional area (p = .024), hippocampal volume

with those in the global brain measures; Aβ1–40 was generally cor-

(p = .013), total gray matter thickness (p = .007), and total surface area

related with increased gray matter thickness and surface area, while

(p = .006). The correlation with total gray matter thickness and total

p-tau181 was generally correlated with decreased gray matter thick-

surface area was significant (controlling FDR at 0.05) after applying the

ness and surface area of brain structures. Of these brain regions,

Benjamini-Hochberg correction for multiple comparisons. The direction

only the gray matter thickness in the fusiform gyrus was signifi-

of each regression coefficient was positive; higher concentrations of

cantly correlated with age, after correction for multiple comparisons

Aβ1–40 were associated with larger brain size. Likewise, p-tau181 con-

(uncorrected p = 3.68 × 10−14). Fitting a linear regression model for

centrations were correlated with cerebral volume (p = .001), cerebel-

fusiform gyrus gray matter thickness using both CSF p-tau181 and

lar volume (p = .039), corpus callosum cross-sectional area (p = .018),

age at MRI scan as covariates, we found that both age (β = 0.20,

hippocampal volume (p = .039), and total surface area (p = .008). The

p = 1.03 × 10−6) and p-tau181 (β = 0.20, p = .0015) were strong pre-

correlation with cerebral volume and total surface area was significant

dictors. This pattern remained even after including age at CSF draw

after the Benjamini-Hochberg correction. In contrast with Aβ1–40, the

(p = .00057 for p-tau181), suggesting that the contributions of CSF

sign of each regression coefficient was negative; that is, higher concen-

Aβ1–40 and p-tau181 on regional brain volume measurements that

trations of p-tau181 tended to be associated with smaller brain sizes.

we have identified are independent of age.

Because we observed suggestive association between Aβ1–40
and p-tau181 and multiple neuroimaging traits, we further tested
for associations between CSF concentrations of Aβ1–40 and p-tau181
and regional measures of gray matter thickness and surface area
across the cortex (Table S1). MRI measurements were adjusted for
age and sex, and the residuals were used for downstream analyses.

3.4 | Heritability and genetic mapping of
CSF biomarkers
We first sought to quantify the heritability of CSF Aβ1–40, Aβ1–42, tau,

and p-tau181 concentrations. Narrow-sense polygenic heritability (h2)
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Cerebellar Volume

Hippocampal Volume

Corpus Callosal
Cross−sectional Area

Total Grey Matter
Thickness

Total Surface Area

p−tau181

tau

Aβ1−42

Aβ1−40

Cerebral Volume

F I G U R E 1 Associations between global measures of brain size and CSF biomarkers (Aβ1–40, Aβ1–42, tau, and p-tau181) in 209 vervets with
both CSF collection and MRI scan. Colored points denote the strength of association – non-significant association (p > .05, black), suggestive
association (p < .05, yellow), and significant association (Benjamini-Hochberg corrected p < .05, red)
was estimated using SOLAR, taking into account age and sex as pos-

CAE4_67028748, Figure S7). Genes within 500,000 base pairs of this

sible covariates. After correcting for relatedness, CSF Aβ1–40 (p = .001)

marker included MAP1B, MRPS27, PTCD2, ZNF366, TNPO1, FCHO2,

and p-tau181 (p = .01) were significantly correlated with age, but not

TMEM171, and TMEM174.

Aβ1–42 (p = .46) or tau (p = .31). CSF p-tau181 (p = .007) but not Aβ1–40
(p = .32), Aβ1–42 (p = .25), or tau (p = .14) was significantly correlated
with sex. The CSF concentration of Aβ1–40 was found to be signifi-

4 | DISCUSSION

and p-tau181 were not heritable (h2 = 0.05, p = .35; h2 = 0.07, p = .15;

We report the measurement of CSF biomarkers in a colony of vervet

and h = 0, p = .50, respectively).

monkeys, a potentially valuable nonhuman primate model for neuro-

cantly heritable (h2 = 0.22, p = .01). CSF concentrations of Aβ1–42, tau,
2

Because of the demonstrated heritability of CSF Aβ1–40 concentra-

degenerative diseases. This dataset spans vervet monkeys of vary-

tion, we then attempted to map genetic loci that could play a role in

ing age, from 1 year of age to 27 years of age. For context, vervets

the phenotypic variation using genome-wide multipoint linkage anal-

typically live to 11–13 years of age in the wild, and about 25 years in

ysis. At a LOD score threshold of 3.3, no markers reached genome-

captivity (Magden et al., 2015). As AD and other neurodegenerative

wide significance (Figure S6). Two peaks were suggestive for linkage

diseases are highly age-related in humans, the study of this large data-

(LOD > 1.9), including a 9 cM region on vervet chromosome 4, be-

set is ideal for dissecting the applicability of vervets in human disease.

tween 67 Mb and 74 Mb (maximum LOD of 2.5) and a 6 cM region

AD in humans is thought to result in decreased CSF Aβ1–42 by ac-

on vervet chromosome 12, between 30 Mb and 37 Mb (maximum

cumulation of Aβ1–42 in neuritic plaques (Fagan et al., 2006) resulting

LOD of 2.2). We additionally performed association as a complemen-

in reduced drainage through the CSF (Lautner et al., 2014; Strozyk,

tary mapping approach, correcting for family structure using a linear

Blennow, White, & Launer, 2003), and in increased tau by neuronal

mixed model approach implemented using the EMMAX software

death (Franz et al., 2003; Itoh et al., 2001) and active secretion (Chai,

(Kang et al., 2010). No markers reached genome-wide significance,

Dage, & Citron, 2012; Saman et al., 2012). Phospho-tau, unlike total

but a suggestive association was identified on chromosome 4 near the

tau, seems to have greater specificity to neurofibrillary tangle pathol-

proximal end of the linkage peak (minimum p = 5.68 × 10−8 at marker

ogy, and does not drastically increase in some neurodegenerative
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F I G U R E 2 Regional associations of
cortical gray matter thickness and CSF
Aβ1–40 in the vervet brain; coloration of
the region indicates suggestive (p < .05,
orange), and significant association
(Benjamini-Hochberg corrected p < .05,
red)

diseases such as Creutzfeldt-Jakob disease (Itoh et al., 2001) and

et al., 1995), Aβ1–40 predominates in CAA while Aβ1–42 predominates

acute stroke (Hesse et al., 2001). The relationship of CSF Aβ1–40 with

in parenchymal plaques, and this neuropathology is reflected in differ-

AD has been less clear, though CSF Aβ1–40 has been reported as de-

ences in the concentrations of these Aβ species in CSF. Furthermore,

creased in CAA (Verbeek et al., 2009). Here, we found that reduc-

the brain regions most associated with decreased Aβ1–40 in this study

tions in global measures of brain size (such as cerebral volume and

in vervet (predominant occipital cortical involvement, as well as precu-

total brain surface area) were associated with reduced CSF Aβ1–40 and

neus and frontal cortex) mirror the distribution of CAA and subsequent

elevated CSF p-tau181. Taken together with previous observations of

neurodegeneration in humans (Attems et al., 2011; Vinters & Gilbert,

age-related amyloid plaques in the vervet (Kalinin et al., 2013; Lemere

1983). Because of these converging lines of evidence, we speculate

et al., 2004), the relationships with Aβ1–40 and p-tau181 are consistent

that the changes in Aβ1–40 observed correlate with CAA pathology, al-

with a scenario of age-related accumulation of amyloid plaques (in

though further study is required to confirm this hypothesis. In a subset

parenchyma and/or vasculature) corresponding to cerebral atrophy in

of this cohort containing 22 vervets ranging from 11 to 26 years of age

the vervet. Though previous studies have found limited phospho-tau

with neuropathology, amyloid plaque burden increased with age and

immunoreactivity and few neurofibrillary tangles in the vervet brain

correlated inversely with CSF Aβ1–42 levels (Dr. Suzanne Craft, personal

(Lemere et al., 2004), the fact that elevations in p-tau181 levels in CSF

communication). The lack of association with CSF Aβ1–42 with age and

are also correlated with changes in brain morphometry suggest that

with brain regions may reflect inconsistent amyloid plaque burden in

tau pathology may also play a role.

the aged vervet, compared to CAA pathology.

These findings are reminiscent of the observed relationship be-

Moreover, we find evidence for the heritability of CSF Aβ1–40

tween CSF biomarkers and neuroimaging measurements in aging and

concentrations in the vervet. Linkage analysis identified two sug-

neurodegenerative disease in humans. Previous work has demon-

gestive linkage peaks: a wide 9 cM peak on chromosome 4, and a

strated associations between longitudinal changes in Aβ1–42 and p-

narrow 6 cM peak on chromosome 12. The lack of statistical sig-

tau231 and hippocampal volume in AD and mild cognitive impairment

nificance in linkage analysis despite the moderate heritability of

(Chou et al., 2009; De Leon et al., 2006; Hampel et al., 2005; Schuff

CSF Aβ1–40 concentration may suggest a highly polygenic contri-

et al., 2009) as well as in healthy brain aging (Fjell et al., 2010) in hu-

bution to the phenotype. While the signal did not reach genome-

mans. However, we identified significant associations of Aβ1–40, not

wide significance and spanned a wide genomic range, precluding

Aβ1–42, with age, gray matter thickness, and other measures of brain

identification of a single causal gene or variant, our work provides a

size. In vervets (Lemere et al., 2004) and in humans (Attems, Jellinger,

basis for further fine mapping of these regions. Potential candidate

Thal, & Van Nostrand, 2011; Attems, Lintner, & Jellinger, 2004; Gravina

genes in the region include PTCD2 and MAP1B, at the proximal end
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of the linkage peak and approximately 330 and 470 kilobases from

frank cognitive deficits were not observed or ascertained in the

the top associated marker. The pentatricopeptide repeat domain 2

vervet subjects, and the study design was cross-sectional; correla-

gene, encoded by PTCD2, has been observed to be accumulated in

tion with measures of brain structure and function in future lon-

AD brain in citrullinated form, and autoantibodies against PTCD2

gitudinal studies may provide additional insight into the extent of

have been observed in AD patient serum (Acharya et al., 2012). The

neurodegeneration.

microtubule-associated protein 1B, encoded by MAP1B, has been

In vervets, CSF Aβ1–40 decreases with advancing age, correlates

described to bind tau and Aβ (Gevorkian et al., 2008; Hasegawa,

with global and regional measures of brain size, and has a large her-

Arai, & Ihara, 1990). In humans, genome-wide association studies

itable component, suggesting its utility as a biomarker of AD-  or

have demonstrated genetic loci that affect CSF biomarkers, the most

CAA-like changes in this potentially valuable animal model. Aβ1–40

robust being the region surrounding the APOE gene (Cruchaga et al.,

was most closely associated with decreases in gray matter thick-

2013). The linkage analysis here may provide a foothold to discover

ness in the frontal lobe and hippocampus, mirroring the regional

analogous loci for vervets, but further work remains to validate and

vulnerability patterns of AD. However, structural associations were

pinpoint them.

also observed in the occipital lobe and precuneus, regions that are

One observed anomaly was the fact that concentration of total

generally spared early in Alzheimer’s disease and more reminiscent

tau was lower than that for p-tau181 in many CSF specimens. This was

of the distribution of pathology in CAA. Age-related cerebral atro-

unexpected because the phosphorylated species is also reactive to the

phy in the vervet likely involves β-amyloid pathological processes,

antibodies against total tau, and therefore the concentration of total

and Aβ1–40 and p-tau181 appear to be robust biomarkers of these

tau should be an upper bound for that of the phosphorylated spe-

processes, though their sensitivities and correlations to disease pa-

cies. Because the calibration standards and controls were derived from

thology remain important open questions. We have also mapped

human tau, we postulated that non-homology in the epitope region

suggestive linkage peaks on vervet chromosomes 4 and 12 that cor-

may confound the assay. Indeed, we found an amino acid difference

respond to CSF Aβ1–40 concentration and may represent a modifier

in the vervet tau ortholog in the AT120 epitope region that may affect

of neurodegeneration. The aged vervet therefore has the potential

the specificity of the antibody. We speculate that this lack of homol-

to advance our understanding of the genetics, pathogenesis, and

ogy accounts for the aberrant total tau levels that were observed and,

treatment of neurodegenerative disease.

therefore, the measurement of the total tau using the AlzBio3 assay in
vervets must be interpreted with caution. The epitope regions for all
of the other antibodies used to quantify levels of Aβ1–40, Aβ1–42, and
p-tau181 were identical between human and vervet.
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tionship and relative effect sizes of the CSF marker-neuroimaging
relationship are not known. In other words, differences in CSF Aβ
and tau concentrations on a population level in vervet can be confidently correlated to aging and neurodegeneration (after controlling
for aging), but the sensitivity and degree of correlation remains unclear. Although we cannot make a conclusion about the prognostic
power of CSF markers, preliminary data suggests that CSF Aβ1–42 is
a predictor of parenchymal amyloid plaques (Suzanne Craft, personal
communication). Interestingly, neither cerebral volume or p-tau181
were associated with age across the wide range of ages in the vervet
cohort; however, the strongest association was detected between
p-tau181 and cerebral volume, suggesting that at least some of the
associations were not driven by dependency on age. Furthermore,
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